Click here to show YOUR banners on this page and only pay for success

Wire News

Atopic Dermatitis skin clearance with new therapy

Written by editor

More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to clinically meaningful improvements in itch and other important patient-reported outcomes compared to placebo.              

“Atopic dermatitis symptoms such as itch, dry skin, severe pain and inflammation take a heavy burden on patients’ lives as well as on their wellbeing. Patients seek medicines that provide effective and well tolerated treatment options that can address those symptoms and improve their quality of life. Lebrikizumab is an innovative treatment with specific inhibition of IL-13, the central pathogenic mediator in AD. The observed efficacy of lebrikizumab in these studies confirms the potential of this novel treatment, which would be a well-received addition to the atopic dermatitis armamentarium,” said Prof. Dr. med. Diamant Thaçi, Director at the Comprehensive Centre for Inflammation Medicine at the University of Lübeck in Germany, and principal investigator of the ADvocate 2 trial.

Lebrikizumab is a monoclonal antibody (mAb) that binds to the interleukin 13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13Rα1/IL-4Rα (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway. 1-5 IL-13 plays the central role in Type 2 inflammation.6 In AD, IL-13 underlies the signs and symptoms including skin barrier dysfunction, itch, infection and hard, thickened areas of skin.7

In ADvocate 1, 43 percent of patients receiving lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks compared to 13 percent of patients taking placebo. Among those receiving lebrikizumab, 59 percent achieved an EASI-75 response, compared to 16 percent with placebo.

In ADvocate 2, 33 percent of patients taking lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks, compared to 11 percent of patients on placebo. Among those receiving lebrikizumab, 51 percent achieved an EASI-75 response, compared to 18 percent taking placebo.

Within four weeks, patients receiving lebrikizumab experienced statistically significant improvements in skin clearance and itching, as well as improvements in interference of itch on sleep, and quality of life, as measured by key secondary endpoints.

The safety profile of the 16-week period was consistent with prior lebrikizumab studies in AD. Patients taking lebrikizumab, compared to placebo, reported a lower frequency of adverse events in ADvocate 1 (lebrikizumab: 45%, placebo: 52%) and ADvocate 2 (lebrikizumab: 53%, placebo: 66%). Most adverse events across the two studies were mild or moderate in severity and nonserious and did not lead to treatment discontinuation. The most common adverse events in ADvocate 1 and 2 for those on lebrikizumab were conjunctivitis (7% and 8%, respectively), common cold (nasopharyngitis) (4% and 5%, respectively) and headache (3% and 5%, respectively).

“New positive data from the Phase 3 monotherapy studies ADvocate 1 and ADvocate 2 presented at the American Academy of Dermatology Annual Meeting demonstrate that lebrikizumab has the potential to be a leading treatment for a new generation of biologics. Patients need new treatment options that provide high efficacy and better tolerability. This milestone further drives us to continue to focus our efforts on one of the key products in our late-stage pipeline and to progress our commitment to improving the quality of patients’ lives through innovative treatments,” said Karl Ziegelbauer, Ph.D., Almirall S.A.’s Chief Scientific Officer.

Detailed 52-week results from ADvocate 1 and 2, as well as 16-week data from ADhere, the Phase 3 AD study of lebrikizumab with topical steroids, will be disclosed in coming months. Almirall and Eli Lilly and Company plan to submit filings to regulatory authorities around the world by the end of 2022 following completion of the ADvocate studies.

“We look forward to sharing longer term results from ADvocate 1 and 2 this year, which we believe will further highlight that lebrikizumab can provide much needed relief for people who struggle from this chronic, and many times, life-long disease,” said Lotus Mallbris, M.D., Ph.D., vice president of global immunology development and medical affairs at Lilly.

Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. Lilly has exclusive rights for development and commercialization of lebrikizumab in the United States and the rest of the world outside Europe.

Related News

About the author


Editor in chief for eTurboNew is Linda Hohnholz. She is based in the eTN HQ in Honolulu, Hawaii.

Leave a Comment

Share to...